Omada Health, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $260.2M | $169.8M | $122.8M | — |
| Cost of revenue | $89.3M | $66.9M | $52.8M | — |
| Gross profit | $170.9M | $102.9M | $70.0M | — |
| Research and development | $40.7M | $35.9M | $33.7M | — |
| Operating expenses | $182.9M | $146.5M | $136.0M | — |
| Operating income | -$12.0M | -$43.7M | -$66.0M | — |
| Interest expense | $2.5M | $4.5M | $4.7M | — |
| Pretax income | -$12.8M | -$47.1M | -$67.5M | — |
| Income tax expense | $0 | $0 | $0 | — |
| Net income | -$12.8M | -$47.1M | -$67.5M | — |
| Balance Sheet | ||||
| Cash and equivalents | $222.0M | $76.4M | — | — |
| Current assets | $272.9M | $113.1M | — | — |
| Total assets | $305.4M | $150.9M | — | — |
| Current liabilities | $75.7M | $54.0M | — | — |
| Total liabilities | $75.7M | $86.3M | — | — |
| Stockholders' equity | $229.7M | -$384.4M | -$350.1M | -$293.2M |
| Cash Flow Statement | ||||
| Cash from operations | $18.3M | -$34.2M | -$49.7M | — |
| Depreciation and amortization | $5.5M | $4.8M | $4.4M | — |
| Stock-based compensation | $13.0M | $9.4M | $8.7M | — |
| Capital expenditure | $1.3M | $596,000 | $416,000 | — |
| Free cash flow | $16.9M | -$34.8M | -$50.2M | — |
| Impairments | $0 | $0 | $0 | — |
Shares outstanding 59.4M · Free float 86.1%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.